Genetics, Genomics & Molecular Diagnostics News

Pfizer will become the first firm to customize IBM's Watson for Drug Development, combining its proprietary data with licensed and publicly available data.

Arti Rai and Colleen Chien are studying whether the Supreme Court's decisions in Mayo v Prometheus and Bilski v Kappos have had a negative impact on diagnostics innovation.

Partners in the iHope program expect to sequence the genomes of 100 patients and parents in the first year who could not otherwise afford it. 

The single-cell approach enabled them to identify gene expression in rare cell types, highlighting a previously unrecognized role for these cells in diabetes. 

The new investment from healthcare equity firm Essex Woodlands follows a $15 million round the company closed with the same investor this summer.

In PLOS this week: RNA-seq, ChIP-seq to determine metformin response; array-based approach to detect protozoa in blood; and more.

Fast Company takes a look at startups in the nutrigenomic space that aim to offer personalized diet advice.

In a glamorous event, the Breakthrough Foundation gave out more than $25 million in prizes to researchers.

Immunotherapy might treat cancer, but it also appears to come with a risk of a number of side effects, the New York Times reports.

This white paper offers advice from two industry experts, Jill Northup from Medical College of Wisconsin, and Philip Cotter from ResearchDx, on setting up a clinical NGS laboratory. The paper covers the general principles of CLIA certification and their specific application to clinical NGS, as well as considerations on implementing informatics to support validated workflows.

Next-generation sequencing (NGS) of bisulfite-converted DNA to detect methylation status with per-base resolution is currently restricted by input requirements, requiring at least 50 ng of DNA. This Application Note shows how the unique chemistry of the Accel-NGS Methyl-Seq DNA Library Kit enables the construction of high complexity libraries for:

•      Genome-wide methylation analysis from 5 ng of human cell-free DNA (cfDNA).

Humanized NSG and NSG-SGM3 mice are a new preclinical bridge for immune-oncology therapies. Humanized mice are a proven host for engraftment of human tumors or establishment of human immunity following hematopoietic stem cell transplantation. Understanding the interactions between human immune cells and tumors is paramount when devising treatment strategies that prevent tumor evasion of immune cells and improve cytotoxic responses.